|Day Low/High||28.61 / 28.98|
|52 Wk Low/High||25.55 / 35.04|
AstraZeneca shares, meanwhile, were less-than-moved by the news.
Kraft Heinz's offer for Unilever boosted the FTSE 100 in London, but markets were in the red elsewhere.
Wall Street is mostly lower in a quieter end to a record-breaking week in which stocks scored their best winning streak in a quarter century.
Stock futures retreat again on Friday, looking to close out the week on a bum note following Wall Street's best record-breaking run in a quarter century.
Astrazeneca stock rose Friday after the company said that its Lynparza drug fared well in clinical trials of its effectiveness as a breast cancer treatment.
AstraZeneca today announced positive results from its Phase III OlympiAD trial comparing LYNPARZA™ (olaparib) tablets (300mg twice daily) to physician's choice of a standard of care chemotherapy in the treatment of...
Weak earnings and ex-dividend dates drove a correction in stock markets across Europe.
European stocks drifted lower Thursday despite a strong session in Asia as a U.S. dollar retreat and mixed corporate earnings allowed benchmarks to pull back from recent multi-month highs.
European stocks are expected to open mixed Thursday following a solid session in Asia and a pullback for the U.S. dollar.
Here's why the pharmaceutical company is a solid addition to your portfolio.
Jim Cramer compares Allergan's growth to other pharma stocks.
The U.K.'s top business leaders have painted a pessimistic view of Brexit, with more than half of respondents in a survey saying that it is already having a negative impact.
The company's shares jumped 5% midday Friday on rumors that Astrazeneca could buy Acadia.
Benchmarks in Europe were broadly higher after new Iran sanctions boosted oil, while investors focus on corporate earnings and solid jobs data.
European investors looked past weaker manufacturing data and a rate hike from China Friday, preferring to focus on a key jobs report from the U.S. later in the session.
AstraZeneca posted stronger-than-expected earnings in the fourth quarter but was hesitant about 2017.
Here is a round-up of the headlines from Europe.
AstraZeneca posted stronger-than-expected earnings in the fourth quarter but provided cautious 2017 guidance as its blockbuster Crestor drug sales continued to slow in the face of generic competition.
Investors will be listening for details around competition facing key products and plans for capital deployment.
Bristol-Myers suffered another setback when the pharma giant said it would not seek accelerated approval for a combination of two immunotherapy drugs as a treatment for newly diagnosed lung cancer.
U.S. stock futures and shares in London and Asia fall Thursday after Donald Trump offers few details on his policies during his first press conference since winning the U.S. election.
European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.
It happened in the wake of Merck's latest drug approval.
AstraZeneca and Royal Dutch Shell will surprise investors.
GM, Bank of America and AstraZeneca are among today's active movers. Here's how to trade them.